Technology | September 13, 2011

.decimal Inc. Announces Custom Electron Aperture Devices for Radiation Therapy

September 13, 2011 — .decimal Inc. (pronounced dot decimal) announced it received 510(k) clearance from the  U.S. Food and Drug Administration (FDA) to market electron apertures for use with Varian treatment machines. These devices are now available to radiation oncology centers across the United States and Canada.

Electron apertures — also known as electron “cutouts” or collimators by radiation therapy departments — are medical devices required for targeted delivery of electrons to patients in radiation therapy.

An electron aperture is a metal tool implemented in cases of neck and head or breast cancer. It features an opening through which a radiation beam passes during delivery of electrons to a patient with a tumor.

Hospitals and cancer centers across the United States will order electron apertures via the Internet; they often receive the devices already in the mold frames within 24 to 72 hours from receipt of an order.

By providing custom-made electron apertures to radiation oncology centers, .decimal helps reduce the cost of maintaining an on-site mold room.

Cerrobend is an alloy composed of cadmium, lead and tin that can be shaped at relatively low temperatures. It does, however, release toxic fumes that, when produced at a medical facility, have the potential for affecting clinical personnel thus requiring expensive ventilation systems.

With this solution, .decimal provides radiation therapy facilities the ability to focus on treating patients, rather than manufacturing medical devices.

For more information: www.dotdecimal.com/products/ElectronAperture

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...